Plain-English translation of NCT06311682 on ClinicalTrials.gov ↗ · Source last updated · Translation generated ·
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether a medication called tralokinumab—given as under-the-skin injections—works safely and effectively to treat moderate-to-severe eczema (also called atopic dermatitis) in young children and infants. All participants will also use a topical steroid cream. The study will measure how much the medication improves skin symptoms, itching, and quality of life over up to 4 years.
Severe eczema in very young children can be extremely uncomfortable and difficult to manage with steroid creams alone. This medication is designed to work in a new way to calm the immune system and reduce inflammation, offering hope for children whose eczema doesn't improve enough with current treatments.
You likely qualify if…
You likely don't qualify if…
If your child is accepted, they will either receive the new medication plus steroid cream or steroid cream alone (children) for the first 16 weeks—you won't know which—and then everyone receives the medication plus cream for the rest of the study. You'll visit the clinic every 2 weeks for the first year, then every 6 weeks after that, with some visits by phone. The study lasts up to 4 years total, and includes a 4-week safety check-in after treatment ends. At each visit, doctors will assess your child's skin, itching, and overall health.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
United States